Virtual Library

Start Your Search

Takeshi Tsuda



Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-92 - A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations (ID 13034)

      16:45 - 18:00  |  Author(s): Takeshi Tsuda

      • Abstract
      • Slides

      Background

      The efficacy and safety of afatinib (an epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in elderly patients with EGFR mutated non-small cell lung cancer (NSCLC) has not been evaluated. Therefore, the aim of this study was to assess the efficacy and safety of afatinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We prospectively assessed the clinical effects of afatinib as a first-line treatment for elderly (≥70 years) NSCLC patients with EGFR mutations (exon 19 deletion or exon 21 L858R mutation). All patients were initially administered afatinib (30 mg/day) at ten Japanese institutions.

      4c3880bb027f159e801041b1021e88e8 Result

      Between May 2014 and August 2017, 40 patients (13 men, 27 women) with a median age of 77 years (range, 70–85 years) were included in our analysis. All patients had adenocarcinoma. Dose reduction was recognized in 19 patients. The objective overall response and disease control rates were 72.5% and 100%, respectively, and the median progression-free survival and overall survival were 15.2 months and 30.0 months, respectively. Common adverse events included diarrhea, rash/acne, and anemia. Major grade 3 or more toxicities included diarrhea (12.5%), mucositis (7.5%), and pneumonitis (7.5%), respectively. Afatinib treatment was discontinued owing to adverse events of elevation of amylase in 1, liver dysfunction in 1, rash/acne in 1, nail change in 1, anorexia in 2 patients, pneumonitis in 2, and diarrhea in 2. Two treatment-related death because of pneumonitis occurred.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This is the first study that verified efficacy and feasibility of first-line chemotherapy with afatinib of 30mg/day in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. First-line afatinib of 30mg/day could be a preferable treatment in this population.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.